3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
3
Prostatic Neoplasms
2
Neoplasms
2
Smoking
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ototoxicity
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hyperlipoproteinemia Type II
1
Hematologic Neoplasms
1
Hemangioma, Cavernous, Central Nervous System
1
Hearing Loss
1
Head and Neck Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Colitis, Ulcerative
1
Cardiotoxicity
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
daratumumab
1
Watchful Waiting
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangioma, Cavernous, Central Nervous System
×
Atorvastatin
×
1 year
×
Clear all
NCT02603328
2025-08-22
AT CASH EPOC
University of Chicago
Phase 1/2
Completed
80 enrolled
19 charts